Savolitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Savolitinib comprises 43 peer-reviewed publications across 15 journals, 1 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, and Neoplasms. Most recent publication: Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study., Lancet Reg Health West Pac, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
    Suárez C, Larkin JMG, Patel P, et al. · J Clin Oncol · 2023
    PubMed: PMID 36809050 · NCT02819596 (CALYPSO) · Carcinoma, Renal Cell
  2. Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.
    Yu Y, Guo Q, Zhang Y, et al. · Lancet Reg Health West Pac · 2026
    PubMed: PMID 41938023 · NCT04923945
  3. Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.
    Yu Y, Guo Q, Zhang Y, et al. · Lancet Respir Med · 2024
    PubMed: PMID 39270695 · NCT04923945
  4. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
    Schmid S, Früh M, Peters S, et al. · Lancet Oncol · 2020
    PubMed: PMID 32027845 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  5. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
    Pal SK, Tangen C, Thompson IM, et al. · Lancet · 2021
    PubMed: PMID 33592176 · NCT02761057 · Carcinoma, Renal Cell
  6. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
    Lu S, Wang J, Yang N, et al. · Lancet · 2026
    PubMed: PMID 41544643 · NCT05015608 (SACHI) · Carcinoma, Non-Small-Cell Lung
  7. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
    Lu S, Fang J, Li X, et al. · Lancet Respir Med · 2022
    PubMed: PMID 34166627 · NCT02897479
  8. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
    Choueiri TK, Heng DYC, Lee JL, et al. · JAMA Oncol · 2021
    PubMed: PMID 32469384 · NCT03091192 · Carcinoma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT03091192CarcinomaProgression Free Survival (PFS) by Blinded Independent Central Review (BICR)
RECIST tumour assessments every 6 weeks from randomisation until disease progression as defined by Recist 1.1 and confirmed by BICR.
Savolitinib QD7.0 Months
Sunitinib QD5.6 Months

Publications by year

2005–2026: 43 publications.

2005
1
2010
1
2014
2
2015
2
2016
3
2017
2
2018
1
2019
4
2020
3
2021
3
2022
5
2023
3
2024
4
2025
2
2026
7

Publications by indication

Carcinoma, Non-Small-Cell Lung (28)

  • Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
    Clin Lung Cancer · 2026 · PMID 41308232 · NCT03778229
  • Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
    Ann Oncol · 2026 · PMID 41780641 · NCT03944772
  • Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
    Lancet · 2026 · PMID 41544643 · NCT05015608
  • Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
    Nat Commun · 2026 · PMID 41530133 · NCT05163249
  • Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
    J Thorac Oncol · 2026 · PMID 41130408 · NCT03944772

Carcinoma, Renal Cell (5)

  • CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.
    J Clin Oncol · 2026 · PMID 41861260 · NCT02819596
  • Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
    J Clin Oncol · 2024 · PMID 39255440 · NCT02761057
  • Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
    J Clin Oncol · 2023 · PMID 36809050 · NCT02819596
  • First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Cochrane Database Syst Rev · 2023 · PMID 37146227 · NCT02761057
  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
    Lancet · 2021 · PMID 33592176 · NCT02761057

Carcinoma (2)

  • Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.
    Nat Rev Urol · 2022 · PMID 32203306 · NCT03091192
  • Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
    JAMA Oncol · 2021 · PMID 32469384 · NCT03091192

Neoplasms (1)

  • A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers.
    Clin Pharmacol Drug Dev · 2023 · PMID 36808891 · NCT04675021

Colorectal Neoplasms (1)

  • A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer.
    J Gastrointest Cancer · 2024 · PMID 39652198 · NCT03592641

Publications by journal

Trial-results highlights

Clinical studies have investigated Savolitinib for certain types of carcinoma. In a study identified as NCT03091192, researchers assessed Progression Free Survival (PFS) by Blinded Independent Central Review (BICR). This endpoint measures the length of time during and after treatment that a patient lives with the disease without it getting worse, based on regular tumor assessments.

For patients participating in the NCT03091192 study, the Savolitinib once-daily arm reported a median Progression Free Survival of 7.0 months. In the same study, the sunitinib once-daily arm reported a median Progression Free Survival of 5.6 months. These values represent the median time observed in each treatment group for this specific endpoint.

All values presented here are sourced from primary registry reporting. For complete details and clinical decision-making, individual published papers should be consulted.

All Savolitinib publications (43)

2026 (7 papers)

  1. Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.
    Yu Y, Guo Q, Zhang Y, et al. · Lancet Reg Health West Pac · 2026 · Derived
    PubMed: PMID 41938023 · NCT04923945
  2. Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
    Yang JC, Chen YM, Batra U, et al. · Clin Lung Cancer · 2026 · Derived
    PubMed: PMID 41308232 · NCT03778229 (SAVANNAH) · Carcinoma, Non-Small-Cell Lung
  3. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
    Riess JW, Yu HA, Le X, et al. · Ann Oncol · 2026 · Derived
    PubMed: PMID 41780641 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  4. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
    Lu S, Wang J, Yang N, et al. · Lancet · 2026 · Derived
    PubMed: PMID 41544643 · NCT05015608 (SACHI) · Carcinoma, Non-Small-Cell Lung
  5. Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).
    Li A, Feng WN, Li J, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41530133 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  6. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
    Le X, Baik C, Cho BC, et al. · J Thorac Oncol · 2026 · Derived
    PubMed: PMID 41130408 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  7. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.
    Jackson-Spence F, Larkin J, Patel P, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41861260 · NCT02819596 (CALYPSO) · Carcinoma, Renal Cell

2025 (2 papers)

  1. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
    Riess JW, de Langen AJ, Ponce S, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40466026 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  2. Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
    Lu S, Wu L, Wang Q, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39521433 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung

2024 (4 papers)

  1. Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study.
    Yu Y, Ren Y, Fang J, et al. · Ther Adv Med Oncol · 2024 · Derived
    PubMed: PMID 36339926 · NCT02897479
  2. Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.
    Yu Y, Guo Q, Zhang Y, et al. · Lancet Respir Med · 2024 · Derived
    PubMed: PMID 39270695 · NCT04923945
  3. A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer.
    Jia J, Moyer A, Lowe M, et al. · J Gastrointest Cancer · 2024 · Derived
    PubMed: PMID 39652198 · NCT03592641 · Colorectal Neoplasms
  4. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
    Barata P, Tangen C, Plets M, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39255440 · NCT02761057 · Carcinoma, Renal Cell

2023 (3 papers)

  1. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
    Suárez C, Larkin JMG, Patel P, et al. · J Clin Oncol · 2023 · Trial result
    PubMed: PMID 36809050 · NCT02819596 (CALYPSO) · Carcinoma, Renal Cell
  2. A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers.
    Miah K, Vishwanathan K, Scarfe G, et al. · Clin Pharmacol Drug Dev · 2023 · Derived
    PubMed: PMID 36808891 · NCT04675021 · Neoplasms
  3. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Aldin A, Besiroglu B, Adams A, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37146227 · NCT02761057 · Carcinoma, Renal Cell

2022 (5 papers)

  1. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
    Yu HA, Goldberg SB, Le X, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 34389237 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  2. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
    Paik PK, Pfeiffer BM, Vioix H, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 35543963 · NCT02897479
  3. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.
    Maia MC, Salgia M, Pal SK, et al. · Nat Rev Urol · 2022 · Derived
    PubMed: PMID 32203306 · NCT03091192 · Carcinoma
  4. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
    Lu S, Fang J, Li X, et al. · Lancet Respir Med · 2022 · Derived
    PubMed: PMID 34166627 · NCT02897479
  5. Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.
    Li A, Chen HJ, Yang JJ, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 36333268 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2021 (3 papers)

  1. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
    Pal SK, Tangen C, Thompson IM, et al. · Lancet · 2021 · Derived
    PubMed: PMID 33592176 · NCT02761057 · Carcinoma, Renal Cell
  2. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
    Choueiri TK, Heng DYC, Lee JL, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32469384 · NCT03091192 · Carcinoma
  3. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
    Duan J, Xu J, Wang Z, et al. · J Thorac Oncol · 2021 · Background
    PubMed: PMID 32916309 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2020 (3 papers)

  1. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
    Schmid S, Früh M, Peters S, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32027845 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  2. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV, Han JY, Ahn MJ, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32027846 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  3. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Lai GGY, Lim TH, Lim J, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 30676858 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2019 (4 papers)

  1. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.
    Yu HA, Suzawa K, Jordan E, et al. · Clin Cancer Res · 2019 · Background
    PubMed: PMID 29530932 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  2. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
    Wang Z, Cheng Y, An T, et al. · Lancet Respir Med · 2019 · Background
    PubMed: PMID 30017884 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  3. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F, Diao XY, Zhang X, et al. · Cancer Commun (Lond) · 2019 · Background
    PubMed: PMID 30823937 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  4. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
    Hong S, Gao F, Fu S, et al. · JAMA Oncol · 2019 · Background
    PubMed: PMID 29596544 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2018 (1 paper)

  1. Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
    Gainor JF, Niederst MJ, Lennerz JK, et al. · J Thorac Oncol · 2018 · Background
    PubMed: PMID 26988570 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2017 (2 papers)

  1. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
    Choueiri TK, Halabi S, Sanford BL, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28199818 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  2. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
    Blakely CM, Watkins TBK, Wu W, et al. · Nat Genet · 2017 · Background
    PubMed: PMID 29106415 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2016 (3 papers)

  1. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
    Middleton G, Crack LR, Popat S, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26410619 · NCT02117167 (SAFIR02_Lung)
  2. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Masters GA, Temin S, Azzoli CG, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26324367 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  3. Cancer statistics in China, 2015.
    Chen W, Zheng R, Baade PD, et al. · CA Cancer J Clin · 2016 · Background
    PubMed: PMID 26808342 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2015 (2 papers)

  1. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC, Wu YL, Nakagawa K, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 26159065 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  2. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Reck M, Popat S, Reinmuth N, et al. · Ann Oncol · 2015 · Background
    PubMed: PMID 25115305 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2014 (2 papers)

  1. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
    Shi Y, Au JS, Thongprasert S, et al. · J Thorac Oncol · 2014 · Background
    PubMed: PMID 24419411 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung
  2. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
    Jia H, Dai G, Weng J, et al. · J Med Chem · 2014 · Background
    PubMed: PMID 25148209 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2010 (1 paper)

  1. Implications of key trials in advanced nonsmall cell lung cancer.
    Bonomi PD · Cancer · 2010 · Background
    PubMed: PMID 20087963 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

2005 (1 paper)

  1. Adjuvant chemotherapy in completely resected non-small-cell lung cancer.
    Pisters KM, Le Chevalier T · J Clin Oncol · 2005 · Background
    PubMed: PMID 15886314 · NCT05163249 (FLOWERS) · Carcinoma, Non-Small-Cell Lung

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).